top of page

Mitchell Kronenberg, Ph.D

Praespero - An Autoimmune Research Fund LOGO 10_rEVERSE.png

Mitchell Kronenberg, Ph.D. Scientific Advisory Board Member, Praespero Professor and President Emeritus, Center for Autoimmunity and Inflammation and Center for Vaccine Innovation, La Jolla Institute for Immunology


Key Achievements

  • Named a Distinguished Fellow of the American Association of Immunologists (AAI) in its inaugural 2019 class of 52 immunologists, which included five Nobel Laureates

  • Recipient of a Merit Award from the National Institutes of Health and the AAI Distinguished Service Award

  • Secured a $3.7 million, four-year NIH R01 grant, building on proof-of-concept work made possible by Praespero support

  • Identified stem-like T cells in the inflamed intestine as a possible driver of chronic inflammatory bowel disease

  • Built an international collaboration to define how MAIT cells contribute to primary biliary cholangitis (PBC)

ABOUT


A world expert in T cell biology, Mitchell Kronenberg has spent his career investigating how the immune system defends and maintains the body's tissues. He earned his Ph.D. from Caltech in 1983, completed his postdoctoral work there, and joined the UCLA School of Medicine faculty in 1986, rising to full professor. In 1997 he came to the La Jolla Institute for Immunology (LJI) as Head of the Division of Developmental Immunology, and in 2003 he was appointed LJI's President, a role he held for many years as the Institute grew into a global leader in immunology. His lab focuses on innate-like T cells and innate lymphoid cells, which reside in tissues such as the lung, liver, and skin, and on mucosal immunology and the development of inflammatory bowel disease (IBD).


His contributions have been recognized with honors including a Burroughs Wellcome Fund Visiting Professorship at Harvard University, the Joseph S. Ingraham Lecture at the Indiana University School of Medicine, election as a Fellow of the American Association for the Advancement of Science, and the San Diego Business Journal's recognition as a most admired CEO. He is also among the most highly cited immunologists in the world, a distinction held by fewer than half of one percent of publishing scientists. 


On Praespero's Scientific Advisory Board, he is instrumental in catalyzing collaborations across labs and borders.


With Praespero's support, Dr. Kronenberg's team studied how T cells are educated in the human thymus, in partnership with SAB member Hilde Cheroutre. This work contributed to a publication in Nature Immunology and helped secure a $3.7 million NIH grant. After hearing Innovation Award winner Andrew Mason speak at a Praespero summit, Dr. Kronenberg launched a joint U.S.-Canadian effort to define the role of MAIT cells in organ-specific autoimmune diseases, beginning with PBC.


In IBD, his team analyzed T cells from inflamed and uninflamed intestine and healthy controls. They found a population of stem-like T cells that can renew themselves and continually give rise to the disease-causing T cells. These cells are enriched in inflamed tissue and validated in mouse genetic models. Their findings suggest that targeting stem-like T cells may be key to lasting remission. He presented this work at the 2023 Praespero Summit, where feedback and discussion helped sharpen the concept.

bottom of page